SELLAS Life Sciences Group
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
7 Times Sq Ste 2503, New York City, New ...Website
www.sellaslife.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
About SELLAS Life Sciences Group
SELLAS Life Sciences Group Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SELLAS Life Sciences Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
SELLAS Life Sciences Group, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when SELLAS Life Sciences Group launches new products
Funding: Get notified immidiatlly once SELLAS Life Sciences Group has new funding data
Earning: See what the market has to say on SELLAS Life Sciences Group recently announced quarterly report
Check if SELLAS Life Sciences Group has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at SELLAS Life Sciences Group
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if SELLAS Life Sciences Group is spiking on competitors!
Click to see if SELLAS Life Sciences Group had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at SELLAS Life Sciences Group
Find 2 more new buyers
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SELLAS Life Sciences Group
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company dedicated to developing novel therapies for various cancer indications. Their product pipeline includes galinpepimut-S, an immunotherapeutic agent targeting the WT1 protein, and SLS009, a highly selective CDK9 inhibitor. The company aims to address diverse hematological cancers... Read More
